EMEA-001350-PIP02-13-M04
Key facts
| Invented name |
Zydelig
|
| Active substance |
Idelalisib
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0345/2018
|
| PIP number |
EMEA-001350-PIP02-13-M04
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of mature B-cell neoplasms
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Gilead Sciences International Limited
Tel. +44 (0)1223 897300 |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|